Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average recommendation of “Moderate Buy” by the twenty-two brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $178.71.

A number of analysts have commented on the stock. Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Needham & Company LLC lowered their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research report on Wednesday, November 27th. Robert W. Baird decreased their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sunbelt Securities Inc. lifted its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Nkcfo LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth about $43,000. UMB Bank n.a. raised its position in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 197 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $59,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Down 2.7 %

Shares of NASDAQ SRPT opened at $124.49 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12 month low of $94.75 and a 12 month high of $173.25. The company has a market cap of $11.89 billion, a price-to-earnings ratio of 99.59 and a beta of 0.77. The business has a fifty day simple moving average of $122.13 and a 200-day simple moving average of $131.40.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.